Filing Flows › Atara Biotherapeutics (ATRA) › Q1 2026 › vs Q4 2025
Atara Biotherapeutics (ATRA) Q1 2026 vs Q4 2025 (quarter over quarter)
Atara Biotherapeutics's revenue fell $1.1M (-68%) from $1.6M in Q4 2025 to $516K in Q1 2026.
Atara Biotherapeutics, Q1 2026: revenue $516K (-100% year over year), operating margin -652.9%, net loss $4.1M, operating cash flow −$3.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $516K | $1.6M | −$1.1M | -68% |
| Net loss | $4.1M | $3.4M | $739K | +22% |
| Costs & expenses | $4.7M | $5.0M | −$340K | -7% |
| Operating costs | $3.9M | $4.2M | −$273K | -7% |
| Interest & other, net | $776K | $843K | −$67K | -8% |
| Operating cash sources | $4.1M | $3.4M | $739K | +22% |
| Depreciation & amortization | $29K | $49K | −$20K | -41% |
| Share-based compensation | $749K | $1.5M | −$768K | -51% |
| Working capital & other | $294K | −$3.9M | $4.2M | — |
| Cash used in operations | $3.1M | $5.7M | −$2.6M | -46% |
| Net loss absorbed | $4.1M | $3.4M | $739K | +22% |
Questions
How much did Atara Biotherapeutics's revenue grow quarter over quarter in Q1 2026?
Atara Biotherapeutics's revenue fell $1.1M (-68%) from $1.6M in Q4 2025 to $516K in Q1 2026.